Boston Scientific Corporation has seen a flurry of activity recently. The corporation has put up its 24-acre Minnetonka Complex for sale and its insiders also sold US$2.3m in stock. Forbes and Leerink Partners gave Boston Scientific an outperform rating and it was upgraded to Buy by Needham. Its sales could potentially grow up to 17% this year. The company's Chief Financial Officer, Dan Brennan, will retire and be succeeded by Jon Monson. Boston Scientific has completed a €1.5 billion offering of senior notes. Its Q1 2025 earnings showcased its leadership in the Medical Devices & Supplies market segment. The stock has shown a robust growth of 173% in the past five years and 33% annually. However, it has also experienced a dip evidenced by its decline while the market was improving. There are predictions of the potential for further growth, backed by its performance and favourable ratings from prominent entities in the stock market like Marshall Wace LLP, TD Cowen, and Wall Street analysts. Boston Scientific's recent Q1 2025 earnings call revealed a strong growth and an upgrade, and the company has set another Q1 earnings date to detail their 2025 performance.
Boston Scientific Corp BSX News Analytics from Wed, 23 Oct 2024 07:00:00 GMT to Sat, 21 Jun 2025 22:20:09 GMT -
Rating 5
- Innovation 7
- Information 7
- Rumor -3
